Is Europe competitive enough in Life Sciences innovation ?
Franck Lescure has joined Auriga Partners in 2004. He is in charge of Life Sciences investments and manages Auriga Partners commitments in Amoéba (Euronext: AMEBA), Cytoo, EnobraQ, Erytech Pharma (Euronext: ERYP), Fab’entech, Median Technologies (Alternext: ALMDT), Pherecydes, and Pylote. He manages the Fund Auriga IV Bioseeds specialized in Infectiology and Microbiology.
Before Auriga Partners, he has been part of the Venture Capital team of Crédit Lyonnais Private Equity (now Omnes Capital), after five years spent in the commercial and medical department of the Air Liquide group. He started his career as a scientist in 1990 at Genset, one of the first French biotech startups.
Franck is an alumnus of the Ecole Normale Supérieure and the Institut Pasteur. He holds a PhD in Microbiology and Virology and a MBA from the Collège des Ingénieurs.